中島 振一郎

Medicine & Life Sciences

1. Alzheimer Disease 26%
2. AMPA Receptors 7%
3. Amyloid 13%
4. Antidepressive Agents 10%
5. Antipsychotic Agents 59%
6. Biomarkers 7%
7. Brain 13%
8. Clinical Trials 14%
9. Clozapine 19%
10. Cognition 19%
11. Cognitive Dysfunction 24%
12. Corpus Striatum 17%
13. Cross-Sectional Studies 6%
14. Datasets 5%
15. Dementia 6%
16. Demography 5%
17. Depression 21%
18. Dopamine 21%
19. Dopamine D2 Receptors 30%
20. Dopamine D3 Receptors 9%
21. Electroencephalography 6%
22. Equipment and Supplies 6%
23. Glutamic Acid 20%
24. Glutamine 7%
25. Gyrus Cinguli 12%
26. Hippocampus 7%
27. Magnetic Resonance Imaging 5%
28. Magnetic Resonance Spectroscopy 7%
29. Major Depressive Disorder 16%
30. Mental Disorders 8%
31. Meta-Analysis 26%
32. Mirtazapine 6%
33. naxagolide 28%
34. Neuroimaging 13%
35. Neurophysiology 10%
36. Olanzapine 15%
37. Polypharmacy 6%
38. Positron-Emission Tomography 21%
39. Prefrontal Cortex 11%
40. Proton Magnetic Resonance Spectroscopy 23%
41. Psychotic Disorders 16%
42. Raclopride 17%
43. Regression Analysis 6%
44. Risperidone 12%
45. Schizophrenia 100%
46. Systematic Reviews 41%
47. Therapeutics 14%
48. Transcranial Magnetic Stimulation 24%
49. Treatment-Resistant Depressive Disorder 6%
50. Ventral Striatum 16%